Navigation Links
MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
Date:9/16/2008

Study 009 meets its primary endpoint of non-inferiority to a rapid-acting

insulin analog

VALENCIA, Calif., Sept. 16 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today released preliminary top-line results from a Phase 3 clinical study of the Technosphere(R) Insulin System in patients with type 1 diabetes (Study 009). This study compared the safety and efficacy of prandial inhalations of Technosphere Insulin (the TI group) versus prandial subcutaneous injections of insulin aspart (the comparator group). Both groups also received daily subcutaneous injections of a basal insulin (insulin glargine).

Study Highlights

Technosphere Insulin, compared to a rapid-acting insulin analog, showed:

* Comparable reductions in A1C levels

* Comparable numbers of patients reaching pre-defined A1C goals

* Superior fasting blood glucose levels

* Better early post-prandial glucose control

* Fewer patients experiencing hypoglycemic events

* Weight loss versus weight gain

* No adverse effects on pulmonary function

Dr. Peter Richardson, MannKind's Chief Scientific Officer, commented, "We are very pleased with the results of this study, the first of our three completed pivotal Phase 3 studies. These observations confirm the results of earlier studies and build on the important differentiating features of this product, including its positive effects on fasting glucose levels. Technosphere Insulin promises to be an important additional option for the treatment of patients with type 1 diabetes. Our next step is to lock the databases for the remaining two pivotal studies, which further examine long-term efficacy and safety in patients with diabet
'/>"/>

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. MannKind Addresses Pfizers Announcement Regarding Exubera
2. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
3. Nutrition 21 Reports That National Toxicology Program Studies Support the Safety of Chromium Picolinate
4. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
5. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
6. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
7. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
8. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
9. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
10. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
11. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: ... of Fair Trading (OFT) approval condition to the announced tender ... (NASDAQ: VPHM).   As a result of the ... and Shire expects to complete the tender offer on January ... the satisfaction of all of the remaining conditions to the ...
(Date:1/15/2014)... 15, 2014  Manufacturers, suppliers and distributors ... be able to protect their most important ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) ... Medical Device Industry, it steadfastly remains one ... cases involving IP infringement. This litigious nature ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ... less than 10 bps, yet are surprisingly capable in ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... Nasdaq: NVGN ), announced today that following ... held on 7 May, 2012, its Board of Directors ... Marshall Edwards, Inc. ("MEI") under the MEI rights offering ... rights that have not been otherwise exercised by MEI ...
... 2012  Marshall Edwards, Inc. (Nasdaq: MSHL ), ... novel therapeutics targeting cancer metabolism, announced that its majority ... million of Units, subject to availability, in Marshall Edwards, ... Novogen stockholders in Sydney on Monday. Pursuant ...
Cached Medicine Technology:Novogen Board Approves US$4 Million Investment In Marshall Edwards Rights Offering 2Marshall Edwards Receives $4 Million Subscription From Novogen In Rights Offering 2Marshall Edwards Receives $4 Million Subscription From Novogen In Rights Offering 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... Voters in New Television Ad, SACRAMENTO, Calif., Oct. ... a new television spot featuring Senator Diane Feinstein,who, speaking ... terrible mistake for California. It,s about discrimination and we ... moved to have the strong, trusted and independent voice ...
... drug delayed disease progression, researchers found , , WEDNESDAY, Oct. ... to treat erectile dysfunction, appears effective in treating pulmonary ... high blood pressure in the arteries that supply the ... can become tired, dizzy and short of breath, because ...
... BIRMINGHAM, Ala. and NASHVILLE, Tenn., Oct. 28 /PRNewswire-FirstCall/,-- ... that the PICA Group,will become part of ProAssurance ... Group (PICA) is the nation,s leading provider of ... 9,800,podiatric physicians in 47 states and the District ...
... 28 Align,Technology, Inc. (Nasdaq: ALGN ) today reported ... 30, 2008., Total net revenues for the third quarter ... million reported in the third quarter of,2007 (Q3 07) and ... (Q2 08)., On a generally accepted accounting principles (GAAP) ...
... Oct. 28 Blue Mountain Quality,Resources, Inc. ... Mountain Regulatory Asset Manager(R) to satisfy their ... of their enterprise-wide,SAP(R) implementation., "Alexion is ... productivity in,its manufacturing facilities and other operations," ...
... New Findings Suggest Soy Isoflavones Contribute to Blood Vessels, Healthy ... ... study examines how a certain,naturally-occurring component of soy may enhance the function ... to,the Center for Disease Control and Prevention, heart disease is the,nation,s number ...
Cached Medicine News:Health News:Cialis May Help Ease Pulmonary Hypertension 2Health News:The PICA Group Will Become Part of ProAssurance 2Health News:The PICA Group Will Become Part of ProAssurance 3Health News:The PICA Group Will Become Part of ProAssurance 4Health News:The PICA Group Will Become Part of ProAssurance 5Health News:The PICA Group Will Become Part of ProAssurance 6Health News:The PICA Group Will Become Part of ProAssurance 7Health News:The PICA Group Will Become Part of ProAssurance 8Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 2Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 3Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 4Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 5Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 6Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 7Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 8Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 9Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 10Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 11Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 12Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 13Health News:Align Technology Announces Third Quarter Fiscal 2008 Results 14Health News:Alexion Pharmaceuticals Chooses Blue Mountain Regulatory Asset Manager(R) for Best-in-class Calibration Management Integrated with SAP(R) 2Health News:Study Shows How Soy Compound Lowers Blood Pressure and Stroke Risk 2
For the quantitative determination of total cholesterol in human serum....
Intended for the quantitative determination of total cholesterol in serum. Single vial, dry powder reagent. Reaction: Endpoint. Wavelength: 500 nm. Linearity: 700 mg/dL (12.9 mmol/L)....
For the quantitative in vitro determination of lithium in serum and plasma. Wavelength: 550 nm. Linear range: up to 4 mm....
This True 12-bit integrated and cooled system is a completely self contained unit built with a long list of standard features including all-electronic-variable transilluminator and EPI lighting....
Medicine Products: